Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A clinical study to investigate if the investigational product, called LN -145 (also known as Tumor Infiltrating Lymphocytes) is safe and be… Recruiting

2024-510778-26-00 Metastatic Non-Small-Cell Lung Cancer 4 2025-12-19
A proof of concept study to evaluate treatments´efficacy by monitoring Minimal Residual Disease using ctDNA in HR-positive/HER2-negative ear… Recruiting

2023-505661-89-00 Early-stage, Hormone Receptor (HR)-positive / Human Epi 4 2025-12-19
A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors Recruiting

2025-521672-60-00 Metastatic or locally advanced SST2-positive neuroendoc 7 2025-12-19
A Phase 3 Study of DZD8586 versus Investigator’s Choice in r/r CLL/SLL Recruiting

2025-522669-32-00 Relapsed/Refractory Chronic Lymphocytic Leukemia/Small 5 2025-12-18
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
RAGNAR: Refractory Advanced diGestive Neuroendocrine carcinomas treated with tARlatamab Recruiting

2024-514327-42-00 Advanced neuroendocrine carcinomas (NECs) of the digest 4 2025-12-18
Study of GS-5319 in Adults With Solid Tumors Recruiting

2025-522397-36-00 Advanced solid tumors 1 2025-12-18
A trial to learn how safe AZD3632 is, how well it works, and how it moves throughout the body over time in adults with acute leukemia and my… Recruiting

2025-521299-76-00 Relapsed or refractory acute leukaemia or Myelodysplast 7 2025-12-18
A clinical study to assess the efficacy of adjuvant immunotherapy with cemiplimab in patients with surgically removed non-small cell lung ca… Recruiting

2024-519901-36-00 Patients with resected stage II-IIIA non-small cell lun 5 2025-12-17
HER2 molecular imaging with 89Zr-trastuzumab PET/CT as a predictive biomarker for antibody-drug conjugate sequencing in patients with advanc… Recruiting

2024-516253-49-01 advanced/metastatic HER2-positive breast carcinoma 4 2025-12-12
Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting

2024-517700-12-00 Rectal cancer 5 2025-12-10
A Study of an IDH1m Inhibitor in Participants with IDH1-Mutated Malignancies and Hepatic or Renal Impairment Recruiting

2024-517923-38-00 Newly diagnosed and/or previously treated IDH1-mutated 3 2025-12-10
Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-… Recruiting

2025-520982-39-00 Philadelphia Chromosome Positive or ABL-class Philadelp 5 2025-12-09
A multicenter, open-label, Phase 2 study of TYRA-300 in non-muscle invasive bladder cancer Recruiting

2025-521277-14-00 Non-muscle invasive bladder cancer (NMIBC) 4 2025-12-09
RVU120 Rollover Study Recruiting

2025-521673-14-00 Relapsed / Refractory Metastatic or Advanced Solid Tumo 4 2025-12-03
Randomized Study to Evaluate Melphalan/HDS Treatment Followed by Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus … Recruiting

2024-520356-24-00 Refractory Metastatic Colorectal Cancer with Liver Domi 4 2025-12-01
Phase II study on the safety and feasibility of stool transplants in limited non-small cell lung cancer patients, using donors who responded… Recruiting

2025-521251-24-00 Non-Small cell lung cancer (NSCLC) 4 2025-12-01
Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting

2024-516906-47-00 Locally Advanced or Metastatic Urothelial Carcinoma 10 2025-11-28
HER2DX-guided diagnostic treatment For patients with HER2-positive early-stage breast cancer Recruiting

2025-521040-37-00 HER2-positive early breast cancer 5 2025-11-26
AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors Recruiting

2025-521707-48-00 KRAS Altered Advanced or Metastatic Solid Tumors 1 2025-11-26
PIRTOBRUTINIB AND GLOFITAMAB IN MANTLE CELL LYMPHOMA Recruiting

2024-512922-27-00 Mantle Cell Lymphoma (MCL) 4 2025-11-25
Upfront trastuzumab-deruxtecan plus capecitabine and bevacizumab for patients with HER2 positive metastatic colorectal cancer: the CHIMERA t… Recruiting

2024-519479-24-00 metastatic colorectal cancer 4 2025-11-21
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors (ARC-20) Recruiting

2024-519142-70-00 Solid Tumors 3 2025-11-19
A first-in-human study to learn how safe BAY 3713372 is and how it works in participants with MTAP-deleted solid tumors Recruiting

2025-520623-24-00 MTAP-deleted Solid Tumors 7 2025-11-19